USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Bowel Disorders Market is Buoyant and Poised for Growth
RELEASE DATE
21-Dec-2012
21-Dec-2012
REGION
North America
North America
Research Code: NBB6-01-00-00-00
SKU: HC02241-NA-MR_07995
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC02241-NA-MR_07995
Description
This research service is focused on the major bowel disorders and evaluates the market for oral and injectable prescription pharmaceuticals for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This research service covers the U.S. market from 2009 to 2017, with 2011 as the base year. Included are products on the market, products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Disease-specific topics including definitions, diagnosis, disease assessment, and clinical treatment guidelines are also outlined and discussed.
Table of Contents
Analysis of the Bowel Disorders Prescription Pharmaceuticals Market in the U.S.
- Executive Summary and Market Overview
Analysis of the Total Bowel Disorders Prescription Pharmaceuticals Market
- Drivers and Restraints
- Forecast and Trends
- Demand Analysis
- Market Share and Competitive Analysis
Analysis of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Segment Breakdown and Market Engineering Measurements
Analysis of the 5-ASA Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Subsegment Breakdown and Market Engineering Measurements
- Treated Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the Corticosteroid Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Subsegment Breakdown and Market Engineering Measurements
- Treated Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the TNF Inhibitor Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Subsegment Breakdown and Market Engineering Measurements
- Treated Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the Non-TNF Biologicals Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Subsegment Breakdown and Market Engineering Measurements
- Treated Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
Analysis of the Novel Orals Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Subsegment Breakdown and Market Engineering Measurements
- Treated Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
Analysis of the Irritable Bowel Syndrome Prescription Pharmaceuticals Segment
Summary and Conclusions
This research service is focused on the major bowel disorders and evaluates the market for oral and injectable prescription pharmaceuticals for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This research service covers the U.S. market from 2009 to 2017, with 2011 as the base year. Included are products on the market, products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Disease-specific topics including definitions, diagnosis, disease assessment, and clinical treatment guidelines are also outlined and discussed.
| No Index | Yes |
|---|---|
| Podcast | No |
| Author | Deborah Toscano |
| Industries | Healthcare |
| WIP Number | NBB6-01-00-00-00 |
| Is Prebook | No |